Indeed, recent reports have provided evidence that such a therapeutic strategy may prove highly effective with the IGF-IR inhibitor NVP-AEW541 when used in combination with an aromatase inhibitor by synergistically inducing apoptosis in aromatase-expressing MCF-7 and T47D cells in vitro [51] and with a novel anti-IGF-IR antibody when combined with tamoxifen-suppressing breast tumour cell growth in vivo [52]. The gene discussed is CYP19A1; the disease is breast neoplasm.